Loading patent…
AssigneeBoard of Trustees of Michigan State University
InventorMagdy Ahmad
Estimating the term…
Compositions and methods for use for treating, pulmonary hypertension, in particular neonatal pulmonary hypertension and early lung inflammation, are described. In a first embodiment, the composition comprises pulmonary vasodilators and mitochondrial targeted antioxidants in mixture with a lung surfactant. Preferably, the composition comprises one or more chemicals selected from the group consisting of a long-acting nitric oxide donors, antioxidants, endothelin-1 receptor antagonists, and antithromboxanes in mixture with a lung surfactant. In a second embodiment, the present invention provides a composition for treating neonatal pulmonary hypertension and early lung inflammation in mammals who do not respond to nitric oxide treatment alone. In this embodiment, the composition comprises liposomes comprising a pulmonary or lung surfactant and which contains vasodilators and chemicals which modulate development of acute inflammation. In a preferred embodiment, the liposome contains a long-acting nitric oxide donor, a recombinant human IκB-α, an NF-κB inhibitor, an anti-TNF-α, and an iNOS inhibitor. The composition can further include one or more of the components comprising the first embodiment.
1- A method for treating pulmonary hypertension in a patient, which comprises:
2- The method of claim 1 wherein the vasodilator is a long acting nitric oxide donor.
3- The method of claim 2 wherein the vasodilator is selected from the group consisting of isosorbide dinitrate, hydralazine, minoxidil, nitric oxide gas, and combinations thereof.
4- The method of claim 1 wherein the antioxidant is coenzyme Q10.
5- The method of claim 1 wherein the antithromboxane is selected from the group consisting of prostacyclin, and sulotroban.
6- The method of claim 1 wherein the patient is an infant.
7- A method for treating pulmonary hypertension in a patient, which comprises:
8- The method of claim 7 wherein the vasodilator is a long acting nitric oxide donor.
9- The method of claim 8 wherein the vasodilator is selected from the group consisting of isosorbide dinitrate, hydralazine, minoxidil, nitric oxide gas, and combinations thereof.
10- The method of claim 7 wherein the antioxidant is coenzyme Q10.
11- The method of claim 7 wherein the antithromboxane is selected from the group consisting of prostacyclin, and sulotroban.
12- The method of claim 7 wherein the patient is an infant.
13- A composition comprising:
14- The composition of claim 13 wherein the vasodilator is a long acting nitric oxide donor.
15- The composition of claim 14 wherein the vasodilator is selected from the group consisting of isosorbide dinitrate, hydralazine, minoxidil, nitric oxide gas, and combinations thereof.
16- The composition of claim 13 wherein the antioxidant is coenzyme Q10.
17- The composition of claim 13 wherein the antithromboxane is selected from the group consisting of prostacyclin, and sulotroban.
18- A composition comprising:
19- The composition of claim 18 wherein the vasodilator is a long acting nitric oxide donor.
20- The composition of claim 19 wherein the vasodilator is selected from the group consisting of isosorbide dinitrate, hydralazine, minoxidil, nitric oxide gas, and combinations thereof.
21- The composition of claim 18 wherein the antioxidant is coenzyme Q10.
22- The composition of claim 18 wherein the antithromboxane is selected from the group consisting of prostacyclin, and sulotroban.
23- A method for treating pulmonary hypertension in a patient, which comprises:
24- The method of claim 23 wherein the vasodilator is a long-acting nitric oxide donor.
25- The method of claim 23 wherein the chemicals which modulate development of acute inflammation comprise recombinant IκB-α, an inhibitor of activation of NF-κB, anti-TNF-α, and an iNOS inhibitor and peroxynitrite scavenger.
26- The method of claim 25 wherein the anti-TNF-α is a recombinant polypeptide comprising the TNF-α receptor.
27- The method of claim 24 wherein the iNOS inhibitor and peroxynitrite inhibitor is mercaptoethylguanidine.
28- The method of claim 24 wherein the inhibitor of activation of NF-κB is a dithiocarbamate.
29- The method of claim 24 wherein the liposome is mixed with a composition which comprises a vasodilator, an antioxidant, an endothelin-1 receptor antagonist, and an antithromboxane in a mixture with a pulmonary or lung surfactant.
30- The method of claim 24 wherein the patient is an infant.
31- The method of claim 24 wherein the patient has pulmonary hypertension which does not respond to nitric oxide treatment.
32- A composition which comprises:
33- The composition of claim 32 wherein the vasodilator is a long-acting nitric oxide donor.
34- The composition of claim 32 wherein the chemicals which modulate development of acute inflammation comprise recombinant IκB-α, an inhibitor of activation of NF-κB, anti-TNF-α, and an iNOS inhibitor and peroxynitrite scavenger.
35- The composition of claim 32 wherein the anti-TNF-α is a recombinant polypeptide comprising the TNF-α receptor.
36- The composition of claim 32 wherein the iNOS inhibitor and peroxynitrite inhibitor is mercaptoethylguanidine.
37- The composition of claim 32 wherein the inhibitor of activation of NF-κB is a dithiocarbamate.
38- The composition of claim 32 wherein the composition further comprises an antioxidant, an endothelin-1 receptor antagonist, and an antithromboxane in a mixture with a pulmonary or lung surfactant.